Adnan Nagrial

机构：Camden and Campbelltown Hospitals, The University of Sydney, Blacktown & Mount Druitt Hospital, Westmead Hospital, Migration Institute of Australia, Westmead Institute · ORCID：0000-0003-0275-2479

发表论文 382 篇 · 总被引 26858 次 · h-index 53

代表论文

• Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis (2025 · Lung Cancer · 被引 3)
• 1342 First-in-human dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and initial efficacy of mRNA-LNP MT-302 in vivo CAR therapy in solid tumors (2025 · 被引 3)
• Supplementary Table S1 from Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial (2026)
• Data from Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial (2026)
• Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance (2026 · Clinical Cancer Research)
• Supplementary Table S1 from Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts (2026)